Skip to main content

Table 1 Histomorphometric parameters of the sciatic nerve after treatment with bupivacaine hydrochloride (BHCl), liposome bupivacaine (LB) and saline in STZ-induced diabetic mice and nondiabetic control mice

From: Neurotoxicity of bupivacaine and liposome bupivacaine after sciatic nerve block in healthy and streptozotocin-induced diabetic mice

   Treated nerves Control nerves
Saline BHCl LB Saline BHCl LB
Fibre density (mm− 2) Diabetic 23724 (6888) 22862 (4349) 30259 (8511) 26232 (4743) 31717 (8258) 23347 (2872)
Nondiabetic 22492 (4881) 21582 (6144)†† 21983 (3408) 25969 (2950) 29522 (3558) 25906 (5004)
Large fibre area per total area Diabetic 65.20 (2.54) 62.63 (7.00) 64.03 (2.50) 67.93 (1.39) 64.58 (3.00) 67.64 (2.00)
Nondiabetic 66.91 (3.61) 63.95 (6.46) 65.71 (2.53) 65.87 (2.39) 65.19 (2.86) 67.72 (1.90)
Large fibre diameter (µm) Diabetic 5.58 (0.65) 5.58
(0.54)
4.97 (0.72) 5.37 (0.48) 4.81 (0.68) 5.62 (0.29)
Nondiabetic 5.82 (0.69) 5.8
(0.75)††
5.68 (0.42) 5.27 (0.38) 4.94 (0.21) 5.42 (0.59)
Axon diameter (µm) Diabetic 3.13 (0.41) 3.53
(0.31)# ††
2.79 (0.68) 2.97 (0.55) 2.85 (0.31) 3.36 (0.32)
Nondiabetic 3.26 (0.49) 3.55 (0.50)†† 3.25 (0.17) 2.98 (0.09) 2.78 (0.16) 3.04 (0.27)
Myelin width (µm) Diabetic 1.23 (0.18) 1.01 (0.17)* 1.09 (0.06) 1.14 (0.12) 1.06 (0.19) 1.14 (0.09)
Nondiabetic 1.28 (0.19) 1.12 (0.29)* 1.21 (0.22) 1.15 (0.20) 1.08 (0.07) 1.19 (0.20)
G-ratio (axon diameter/large fibre diameter) Diabetic 0.56 (0.03) 0.63 (0.04)** ## 0.56 (0.06) 0.55 (0.06) 0.60 (0.09) 0.60 (0.04)
Nondiabetic 0.56 (0.04) 0.62
(0.06)** ##
0.58 (0.05) 0.57 (0.04) 0.56 (0.02) 0.56 (0.03)
  1. Values are means (SD), n = 6 for each study group. From two-way ANOVA: *P < 0.05, **P < 0.01 for BHCl- versus saline-treated nerves, and #P < 0.05, ##P < 0.01 for BHCl- versus LB-treated nerves. From dependent t test: †P < 0.05, †† P < 0.01 between treated and control nerves